Health-care companies slipped as vaccine makers remained under pressure. Shares of Novavax plunged by 8%, compounding losses in the wake of the vaccine developer's earnings report. Rival Moderna lost ...
Among the E coli isolates, there were 124 sequence types (STs), 20 of which were shared among the three countries. The ...
The algorithm was roughly 3% more accurate than the relevant diagnostic code and less biased toward certain populations, the ...
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback